Eye Diseases Clinical Trial
Official title:
The Multicenter Randomized Clinical Trial of Fast-progressing Myopia Control Using Repeated Low-Level Red-Light Therapy and Orthokeratology
The purpose of this multicenter randomized clinical trial is to evaluate the adjunctive effect of repeated low-level red-light therapy (RLRL) and orthokeratology (ortho-k) on myopia control in ortho-k non-responders who have undergone ortho-k treatment but were still experiencing fast myopia progression.
Myopia constitutes a major threat to personal health globally for its increased prevalence. Moreover, its dose-related association with irreversible blindness complications such as myopic macular degeneration have been demonstrated. It is crucial to look for effective ways to control myopia in children to reduce risk of myopic pathologies in later life. Orthokeratology (ortho-k) is the first-line optical method in myopia control, resulting in slowing axial elongation by 43-63%. However, results after ortho-k treatment vary among individuals. Methods with more accurate efficacy and wider application to slowing down myopia progression, especially for myopia with limited ortho-k response, are still urgently required. Repeated low-level red-light (RLRL) therapy is an innovative and non-invasive therapeutic treatment for a variety of eye diseases. Our previous clinical study suggested RLRL could effectively retard myopia progression without clinically observable side effects. The purpose of this study is to evaluate the adjunctive effect of RLRL and ortho-k on myopia control in ortho-k non-responders using a multicenter randomized controlled trial design. Ortho-k non-responders are defined as who have continuously undergone ortho-k treatment but were still experiencing fast myopia progression. The subjects will be randomly assigned to either experimental group (RLRL and ortho-k) or control group (ortho-k). Their axial length will be monitored over one year. Changes in axial length in the two groups will be compared. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05414994 -
Assessment of the Ocular Microbiome in Health and Disease
|
||
Active, not recruiting |
NCT04271709 -
Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT)
|
N/A | |
Completed |
NCT02811692 -
Study for Collection of Aflibercept Data in Routine Practice
|
||
Recruiting |
NCT06045299 -
Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Presbyopia
|
Phase 3 | |
Recruiting |
NCT01521065 -
An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
|
Phase 2 | |
Completed |
NCT04799704 -
Tear Film SARS-nCoV-2 Detection in Symptomatic and Pauci-symptomatic Patients.
|
||
Recruiting |
NCT05876689 -
Swept Source OCT Imaging With the DREAM VG-OCT
|
||
Active, not recruiting |
NCT04123626 -
A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene
|
Phase 1/Phase 2 | |
Recruiting |
NCT04150432 -
Correlation Between Exhaled Propofol Concentration With Plasma Concentration in Children
|
N/A | |
Not yet recruiting |
NCT05550740 -
Repeated Low-Level Red-Light Therapy for Shortening Axial Length
|
N/A | |
Completed |
NCT02332343 -
Sparing of the Fovea in Geographic Atrophy Progression
|
N/A | |
Completed |
NCT01727973 -
Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy
|
Phase 1/Phase 2 | |
Terminated |
NCT01225146 -
Study of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2)
|
Phase 1 | |
Completed |
NCT00333203 -
Next Generation Ophthalmic Irrigating Solution Posterior Segment Study
|
Phase 3 | |
Not yet recruiting |
NCT05565547 -
Multimodal Equipment for Teleophthalmology Assessment (META)
|
||
Recruiting |
NCT05158699 -
Effectiveness of Periocular Drug Injection in CATaract Surgery
|
Phase 3 | |
Recruiting |
NCT06112340 -
A Phase 2b Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
|
Phase 2/Phase 3 | |
Recruiting |
NCT06451172 -
Novel Antisense Oligonucleotide Eye Drops for Treating Antibiotic-Resistant Bacterial Keratitis
|
Early Phase 1 | |
Completed |
NCT05211089 -
Manual Versus Automated Choroidal Thickness Measurements Using Swept-source Anterior Segment OCT
|
||
Not yet recruiting |
NCT06070467 -
Holistic Mixed Approaches to Capture the Real Life of Children With Rare Eye Diseases
|